Showing results (31-40 of 65) with videos related to

Sort By:
Pageof 7
Tumori|October 7, 2005
An unusual case of three synchronous tumors in a young womanRaffaele Longo, Guido Carillio, Antonietta Torrisi, et al.
Journal of Translational Medicine|October 22, 2011
Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT studySandro Barni, Roberto Labianca, Giancarlo Agnelli, et al.
Oncology Reports|July 29, 2003
Comparing the efficacy and safety of fixed versus weight-based dosing of epoetin alpha in anemic cancer patients receiving platinum-based chemotherapyCristina Granetto, Sergio Ricci, Andrea Martoni, et al.
Oncology|September 6, 2007
Diagnosis, management and clinical outcome of bone metastases in breast cancer patients: results from a prospective, multicenter studyMarina E Cazzaniga, Luigi Dogliotti, Stefano Cascinu, et al.
Breast Cancer Research and Treatment|March 4, 2003
The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer pretreated with taxanes and/or anthracyclines: a phase I-II studyAlessandro Morabito, Gianfranco Filippelli, Sergio Palmeri, et al.
Angiogenesis|January 4, 2012
A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancerGiampietro Gasparini, Francesco Torino, Takayuki Ueno, et al.
Cancer Journal (Sudbury, Mass.)|August 2, 2005
The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlatesGiampietro Gasparini, Sabrina Meo, Giuseppe Comella, et al.
Neoplasia (New York, N.Y.)|September 24, 2014
Optimizing single agent panitumumab therapy in pre-treated advanced colorectal cancerGiampietro Gasparini, Fiamma Buttitta, Mario Rosario D'Andrea, et al.
Oncology Reports|July 6, 2006
Trastuzumab in combination with gemcitabine and vinorelbine as second-line therapy for HER-2/neu overexpressing metastatic breast cancerAlessandro Morabito, Raffaele Longo, Domenico Gattuso, et al.
The Lancet. Oncology|September 4, 2009
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind studyGiancarlo Agnelli, Gualberto Gussoni, Carlo Bianchini, et al.
Pageof 7